[Pharmaceutical Network Market Analysis] Medicinal excipients are the general term for ingredients other than the main drug in pharmaceutical preparations, and are also an important part of pharmaceutical preparations, which can affect the safety, effectiveness, stability, compliance and economic value of pharmaceutical preparations. In recent years, under the influence of the continuous deepening of medical reform policies, the intensified upgrading and adjustment of the pharmaceutical industry, the acceleration of medical insurance adjustments, market fluctuations and changes in market demand, my country's pharmaceutical excipients market has begun to grow rapidly.
Statistics show that in 2018, my country's pharmaceutical excipients market has reached 183.501 billion yuan, a year-on-year increase of 15.56%. According to the current development trend, although my country's pharmaceutical excipients started late, the industry predicts that my country's pharmaceutical excipients will also reach 140.6 billion yuan in 2025. However, it should be noted that my country’s drug development path is accustomed to the concept of "heavy raw materials, grasping preparations, and light excipients". During the large-scale development of raw materials and preparation industries, the pharmaceutical excipients industry is still not paying enough attention.
Therefore, in the context of my country’s pharmaceutical excipients market with broad room for development, as well as the background of drug consistency evaluation, national procurement, and policies encouraging the development of high-end preparations, the industry believes that the green development of raw materials is advocated, and the high-quality development of pharmaceutical excipients is already in force. Must do.
It is understood that there are many varieties of domestic pharmaceutical excipients and the standards for pharmaceutical excipients in the Pharmacopoeia need to be improved. As of December 2019, of the 459 pharmaceutical excipient varieties (some products of the same product with different names are combined), only 62% of them have the pharmacopoeial standards of the four regions of China, the United States, Europe and Japan, and only 45% of the varieties have Chinese Pharmacopoeia standards. At the same time, judging from the number of pharmaceutical excipients in the pharmacopoeias of various countries, there is still a big gap between the Chinese Pharmacopoeia and the US Pharmacopoeia.
In addition, the concentration of the domestic pharmaceutical excipients industry also needs to be improved. According to statistics, there are currently about 470 pharmaceutical excipient manufacturers in my country, which are mainly divided into enterprises specializing in the production of excipients, chemical enterprises and food production enterprises. Among them, the number of professional pharmaceutical excipient companies is not high, and most companies are small in scale, single in production, and not many companies with sales of more than 100 million yuan.
On the whole, pharmaceutical excipients, which are an indispensable part of pharmaceutical preparations, must be accelerated to upgrade in order to promote the high-quality development of drugs. So what should we do? The industry believes that the development of new and high value-added excipients will become an important way for pharmaceutical companies to develop in a high-quality direction. In the future, pharmaceutical companies need to consider their safety, compatibility, and functionality more in the process of developing new pharmaceutical excipients. At the same time, it is necessary to accelerate the cultivation of pharmaceutical excipients research and development talents and standardize production.
In general, with the development of my country's pharmaceutical industry, my country's pharmaceutical excipients market will maintain a long-term development trend of rapid growth in the future. But at the same time, with the continuous advancement of related review and consistency evaluation policies, pharmaceutical companies will also need to pay more attention to standardized and standardized production, and accelerate R&D innovation and continuous improvement of quality requirements, in order to promote the high-quality development of the entire industry and further Ensure drug safety.